[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-444659-105":59,"doc-detail-444659-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pralsetinib-induced-lymphocytic-colitis-case-report","Pralsetinib-Induced Lymphocytic Colitis - Case Report","","Lymphocytic colitis (LC), a form of microscopic colitis marked by increased intraepithelial lymphocytes, is classically linked to chronic watery diarrhea and selected medications. Incidence as a treatment-related adverse effect of rearrangement during transfection-selective tyrosine kinase inhibitors is unclear. This report describes pralsetinib-induced LC in a stage 3c nonsmall cell lung cancer patient, highlighting persistent diarrhea refractory to standard antidiarrheal therapy and the need for gastrointestinal evaluation and histopathology for early diagnosis and management.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pralsetinib-induced-lymphocytic-colitis-case-report/444659/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pralsetinib-induced-lymphocytic-colitis-case-report/444659.png","ImageObject",300,407,{"name":92,"@type":93},"Ben ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is lymphocytic colitis in this report, and what symptoms did the patient have?","Question",{"text":112,"@type":113},"LC is a microscopic colitis subtype characterized by chronic watery diarrhea and increased intraepithelial lymphocytes on histology. The patient developed persistent grade 3 diarrhea with abdominal cramping and anorexia during pralsetinib treatment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was pralsetinib-related LC managed in the case?",{"text":117,"@type":113},"Pralsetinib was held when LC was diagnosed, and diarrhea resolved within about one week. Budesonide 9 mg was then used for drug-induced LC, and pralsetinib was restarted with adjusted dosing alongside budesonide to prevent recurrence.",{"name":119,"@type":110,"acceptedAnswer":120},"What diagnostic findings supported the diagnosis of LC?",{"text":121,"@type":113},"Endoscopy showed only mild scattered erythema, while random colon and rectal biopsies demonstrated increased intraepithelial lymphocytes with neutrophilic infiltration and focal crypt abscess formation throughout the colon and rectum, consistent with LC.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},444659,1790812902,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":81,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":39,"preview_page_count":4},2336478951081,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","ACG CASE REPORTS JOURNAL  \nCASE REPORT | COLON  \nPralsetinib-Induced Lymphocytic Colitis  \nMauricio F. Jin, MD 1 , Sarah S. Tawfic, MD 1 , and Xiao Jing (Iris) Wang, MD2  \n1 Division of Internal Medicine, Mayo Clinic, Rochester, MN  \n2Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN  \nABSTRACT  \nLymphocytic colitis (LC) is a subtype of microscopic colitis, often associated with chronic watery diarrhea and characterized by an increase in intraepithelial lymphocytes. Although various medications are implicated in drug-induced LC, its incidence as a treatment-related adverse effect of rearrangement during transfection-selective tyrosine kinase inhibitors is not known. We report a case of pralsetinib-induced LC in a patient with stage 3c nonsmall cell lung cancer. This case highlights pralsetinib-induced LC as a cause of persistent diarrhea that is refractory to standard antidiarrheal treatments and prompts gastrointestinal evaluation and histopathological examination to facilitate early diagnosis and management.  \nKEYWORDS: pralsetinib; RET-selective tyrosine kinase inhibitor; lymphocytic colitis; microscopic colitis; drug-induced colitis; targeted therapy adverse events  \nABBREVIATIONS: GI, gastrointestinal; LC, lymphocytic colitis; NSCLC, non small cell lung cancer; RET, rearrangement during transfection; TKI, tyrosine kinase inhibitor; TRAE, treatment-related adverse event; VEGFR, vascular epithelial growth factor receptor  \nINTRODUCTION  \nPralsetinib is a rearrangement during transfection (RET) selective tyrosine kinase inhibitor (TKI) approved for treatment of metastatic nonsmall cell lung cancer (NSCLC) with RET-fusion and advanced/metastatic radioiodine-refractory thyroid carcinoma with RET-fusion.1 Although considered effective and safe in its treatment of these cancers, it is commonly associated with gastrointestinal (GI) treatment-related adverse events (TRAE).1–3 We report a unique case of pralsetinib-induced lymphocytic colitis (LC) in a patient treated for stage 3c NSCLC.  \nCASE REPORT  \nA 71-year-old woman with no prior GI diagnoses was referred to GI clinic for persistent grade 3 diarrhea and biopsy-proven colitis during treatment with pralsetinib. She was started on pralsetinib400mg after work-up for thoracic back pain and dry cough revealed stage 3c NSCLC. Restaging computed tomography 2 months after initiating pralsetinib demonstrated near complete tumor response.  \nThree months after initiating pralsetinib, patient experienced lower abdominal cramping, anorexia, and persistent grade 3 diarrhea with occasional dark stools. Loperamide only minimally improved her diarrhea. Subsequent laboratory workup was unrevealing for infection. She underwent esophagogastroduodenoscopy and colonoscopy, notable only for mild scattered erythema in the rectosigmoid. Random colonicand rectal biopsies demonstrated an increase in intraepithelial lymphocytes with associated neutrophilicinfiltrate and focal crypt abscess formation throughout the colon and rectum, consistent with LC. Her pralsetinib was held, and her diarrhea resolved1week later. However, restaging positron emission tomography-computed tomography demonstrated new uptake in the left lung concerning for tumor recurrence, and she was restarted on a reduced dose of pralsetinib 200 mg after holding for 2 weeks. Her dosage was increased to 300 mg 1 week after restarting pralsetinib, and she started experiencing grade 2 diarrhea. Pralsetinib was held again. She then received budesonide9mg for drug-induced LC, with resolution ofher diarrhea in1day. She then restarted her pralsetinib 200 mg, with concomitant budesonide, increasing her dose to 300 mg 1 week later, with no recurrence of diarrhea.  \nACG Case Rep J 2026;13:e01943 . doi:10 . 14309/crj.0000000000001943. Published online: January 5, 2026 Correspondence: Xiao Jing (Iris) Wang, MD ([Wang.xiaojing@mayo.edu](Wang.xiaojing@mayo.edu)) .  \nACG Case Reports [Journal / Volume 13 acgcasereports.com 1](Journ","cbCaiqv80LCfOfgd","https://ap.wps.com/l/cbCaiqv80LCfOfgd","pdf",180224,"English","# ABSTRACT\n# INTRODUCTION\n# CASE REPORT\n# DISCUSSION","[{\"question\":\"What is lymphocytic colitis in this report, and what symptoms did the patient have?\",\"answer\":\"LC is a microscopic colitis subtype characterized by chronic watery diarrhea and increased intraepithelial lymphocytes on histology. The patient developed persistent grade 3 diarrhea with abdominal cramping and anorexia during pralsetinib treatment.\"},{\"question\":\"How was pralsetinib-related LC managed in the case?\",\"answer\":\"Pralsetinib was held when LC was diagnosed, and diarrhea resolved within about one week. Budesonide 9 mg was then used for drug-induced LC, and pralsetinib was restarted with adjusted dosing alongside budesonide to prevent recurrence.\"},{\"question\":\"What diagnostic findings supported the diagnosis of LC?\",\"answer\":\"Endoscopy showed only mild scattered erythema, while random colon and rectal biopsies demonstrated increased intraepithelial lymphocytes with neutrophilic infiltration and focal crypt abscess formation throughout the colon and rectum, consistent with LC.\"}]","Pralsetinib-Induced Lymphocytic Colitis - Case Report | PDF",1790708820]